Press release
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Collaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's
About this update from Moderna, Inc.
[{"type":"text","content":"Collaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery systemModerna has acquired an option to license Generation Bio's ctLNP and closed-ended DNA (ceDNA) technology for two immune cell programs and two liver programs, with an additional option for a third immune cell or liver programModerna will fund all research and development activities under the collaborationGeneration Bio will receive a $40 million upfront cash payment, a pre-payment of research funding, plus a $36 million equity investment from Moderna, with the potential for additional milestones, fees, and royaltiesCAMBRIDGE, MA / ACCESSWIRE / March 23, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.\"Moderna continues to invest in innovative technology to enable us to develop a breadth of transformative medicines for patients,\" said Rose Loughlin, Ph.D., Moderna's Senior Vice President for Research and Early Development. \"Through this collaboration, which builds on Generation Bio's non-viral genetic medicines platform, we have the potential to target immune cells with diverse nucleic acid cargos and the liver for gene replacement. We are excited to have Generation Bio as our partner as we continue to broaden our therapeutic pipeline and extend the potential benefit of nucleic acid therapeutics to more patients.\"\"Non-viral DNA therapeutics may offer durable, redosable, titratable genetic medicines to patients suffering from rare and prevalent diseases on a global scale,\" said Phillip Samayoa, Ph.D., Chief Strategy Officer of Genera...